Showing 3241-3250 of 5956 results for "".
- Nidek Receives CE Mark Approval for Preloaded IOL Injection Systemhttps://modernod.com/news/nidek-receives-ce-mark-approval-for-preloaded-iol-injection-system/2482315/Nidek has received CE Mark for the NP-1/NP-1C Preloaded IOL Injection System, a fully preloaded injection system with an aspheric hydrophobic soft acrylic lens designed for smoother, safer, and secure IOL implantation. The NP-1/NP-1C injector is developed for smooth, controlle
- Bausch + Lomb Receives Health Canada Approval for enVista Envy Full Visual Range IOLhttps://modernod.com/news/bausch-lomb-receives-health-canada-approval-for-envista-envy-full-visual-range-iol/2482293/Health Canada has approved Bausch+Lomb's enVista Envy full visual range IOL. This is the first regulatory approval of the new lens, which is designed to offer a full range of vision with dysphotopsia tolerance on the enVista IOL platform. “enVista Envy
- Researchers Detail How Neurons Build a 3-D Vascular Structure to Keep the Retina Healthyhttps://modernod.com/news/researchers-detail-how-neurons-build-a-3-d-vascular-structure-to-keep-the-retina-healthy/2482292/Scientists have known for years that a lattice of blood vessels nourishes cells in the retina that allow us to see – but it’s been a mystery how the intricate structure is created. Now, researchers at University of California San Francisco have found a new type of neuron that guides i
- Clearside Biomedical Publishes Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS) Injectionhttps://modernod.com/news/clearside-biomedical-publishes-consensus-guidelines-for-drug-delivery-via-suprachoroidal-space-scs-injection/2482288/Clearside Biomedical announced that new guidelines that represent best practices for injection into the suprachoroidal space have been published in "RETINA, The Journal of Retinal and Vitreous Diseases." The publication, entitled, “Suprachoroidal Space Injection Techniqu
- Johnson & Johnson to Debut EYE-RD Global Registry at ARVOhttps://modernod.com/news/johnson-johnson-to-debut-eye-rd-global-registry-at-arvo/2482261/Johnson & Johnson announced that eight company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting taking place in Seattle from May 5–9, 2024. The company's two oral presentations wil
- Safilo North America Appoints New Leaderhttps://modernod.com/news/safilo-north-america-appoints-new-leader/2482258/Safilo North America announced the appointment of Gabriele Cusani Sodano as president and chief commercial officer, effective April 2024. The company says Mr. Cusani brings a wealth of experience and a proven track record to succeed in this new role, which will focus on accelerating the implement
- BVI’s Podeye Hydrophobic Monofocal IOL Launched in Japanhttps://modernod.com/news/bvis-podeye-hydrophobic-monofocal-iol-launched-in-japan/2482239/BVI Medical announced the launch of the Podeye hydrophobic monofocal intraocular lenses (IOL) in Japan after receiving approval by the Japanese Pharmaceuticals and Medical Devices Agency. Podeye is now available for commercial use and available to surgeons across the country. The Podeye
- Aviceda Therapeutics Announces Formation of European Clinical Advisory Boardhttps://modernod.com/news/aviceda-therapeutics-announces-formation-of-european-clinical-advisory-board/2482218/Aviceda Therapeutics announced the formation of its European Clinical Advisory Board (CAB) made up of internationally recognized thought leaders in retina. The CAB will provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geog
- Aldeyra Plans to Resubmit New Drug Application for Reproxalap in Dry Eye Diseasehttps://modernod.com/news/aldeyra-plans-to-resubmit-new-drug-application-for-reproxalap-in-dry-eye-disease/2482193/About 4 months after receiving a complete response letter (CRL) from the FDA, Aldeyra Therapeutics announced a clinical development plan intended to enable resubmission of a new drug application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry
- Alcon Launches Clareon Presbyopia Correcting IOLs in Indiahttps://modernod.com/news/alcon-launches-clareon-presbyopia-correcting-iols-in-india/2482160/Alcon announced the launch of the Clareon family of IOLs in India. Clareon is designed to deliver consistent visual outcomes and exceptional clarity that lasts and is features a glistening-free IOL material that has among the lowest levels of haze and subsurface nanoglist